Kameel D. Farag, Interim CFO of Akari Therapeutics Plc (NASDAQ:AKTX), filed a Form 4 on November 19, 2026, disclosing two acquisitions of American Depositary Shares on November 17, 2026, both representing restricted stock units.

Key Highlights

  • Two RSU-based acquisitions: Farag acquired 1,284 ADS at $10.12 and 1,589 ADS at $8.18, both on November 17, 2026, via transaction code "A".
  • Resulting ownership: Following the two transactions, Farag directly beneficially owns 26,182 American Depositary Shares, according to the filing.
  • RSU structure: Each RSU represents the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share, per the filing's footnote.
  • Vesting date: The RSUs reported are described as vesting in full on November 15, 2026, according to the filing.
  • Signing authority: The form was signed by Abizer Gaslightwala as Attorney-in-Fact on November 19, 2026.

Farag's November 2026 RSU Acquisitions at Akari Therapeutics

According to the Form 4 filed with the SEC on November 19, 2026, Kameel D. Farag, serving as Interim CFO of Akari Therapeutics Plc (NASDAQ:AKTX), reported two acquisitions of American Depositary Shares on November 17, 2026. The first transaction involved 1,284 ADS at a price of $10.12 per share, and the second involved 1,589 ADS at $8.18 per share. Both transactions carried transaction code "A," indicating acquisition, and both are classified as direct ownership.

The filing's footnote explains that the acquired ADS represent restricted stock units, with each RSU representing the right to receive 80,000 ordinary shares carrying a par value of $0.000000005 per ordinary share. The RSUs are described as vesting in full on November 15, 2026. Following the first reported transaction, Farag's beneficial ownership stood at 24,593 ADS; after the second, it rose to 26,182 ADS, all held directly.

No derivative securities transactions were reported in Table II of the filing. The form was filed by one reporting person and was signed by Abizer Gaslightwala as Attorney-in-Fact for Farag. No amendment date was indicated, and no box was checked to indicate the transactions were made pursuant to a Rule 10b5-1(c) plan.

What Was Disclosed

The filing disclosed two RSU-related acquisitions of ADS by Akari Therapeutics' Interim CFO on November 17, 2026, resulting in direct beneficial ownership of 26,182 ADS, as reported in a Form 4 filed November 19, 2026.